JPEO-CBD issues medical countermeasures broad agency announcement
The announcement said that this funding would take the form of grants. At this time, there is no indication of how many awards are planned to be granted nor is there is no indication of total program funding or award ceilings and floors. This announcement will be continuously open until a revision or cancellation is made.
The JPEO-CBD offers support for the development of long and short-term challenges associated with chemical, biological, radiological and nuclear (CBRN) threats and weapons. The office specializes in the procurement and development of medical countermeasures, detection, diagnostic and identification of CBRN materials and attacks.
The BAA includes specific requirements for medical and diagnostic products. With medical products, the compound must be able to have its capabilities demonstrated in a laboratory setting, and all proposals must indicate the plans to conduct toxicity studies for safety purposes. They should also address the specific threat that the product aims to resolve or provide enhanced treatment capability.
For diagnostics, technology should support architectural development; submitting entities must be willing to conduct pre-clinical studies to meet requirements.
This BAA does not indicate any limitation on what entities may submit proposals.